vs
CBAK Energy Technology, Inc.（CBAT）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
CBAK Energy Technology, Inc.的季度营收约是REGENXBIO Inc.的1.9倍（$58.8M vs $30.3M），CBAK Energy Technology, Inc.净利率更高（-12.5% vs -221.3%，领先208.8%），CBAK Energy Technology, Inc.同比增速更快（131.8% vs 43.0%），CBAK Energy Technology, Inc.自由现金流更多（$16.1M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -0.0%）
CBAK能源科技是一家专业从事锂离子电池研发、生产与销售的企业，产品涵盖高性能电芯、模组及电池包，主要服务新能源汽车、储能系统、消费电子等核心领域，业务覆盖中国及全球多个市场。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
CBAT vs RGNX — 直观对比
营收规模更大
CBAT
是对方的1.9倍
$30.3M
营收增速更快
CBAT
高出88.8%
43.0%
净利率更高
CBAT
高出208.8%
-221.3%
自由现金流更多
CBAT
多$68.9M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-0.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $58.8M | $30.3M |
| 净利润 | $-7.4M | $-67.1M |
| 毛利率 | 7.3% | — |
| 营业利润率 | -13.6% | -190.0% |
| 净利率 | -12.5% | -221.3% |
| 营收同比 | 131.8% | 43.0% |
| 净利润同比 | -63.6% | -31.2% |
| 每股收益（稀释后） | $-0.08 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CBATRGNX
| Q4 25 | $58.8M | $30.3M | ||
| Q3 25 | $60.9M | $29.7M | ||
| Q2 25 | $40.5M | $21.4M | ||
| Q1 25 | $34.9M | $89.0M | ||
| Q4 24 | $25.4M | $21.2M | ||
| Q3 24 | $44.6M | $24.2M | ||
| Q2 24 | $47.8M | $22.3M | ||
| Q1 24 | $58.8M | $15.6M |
净利润CBATRGNX
| Q4 25 | $-7.4M | $-67.1M | ||
| Q3 25 | $2.7M | $-61.9M | ||
| Q2 25 | $-3.1M | $-70.9M | ||
| Q1 25 | $-1.6M | $6.1M | ||
| Q4 24 | $-4.5M | $-51.2M | ||
| Q3 24 | $17.6K | $-59.6M | ||
| Q2 24 | $6.4M | $-53.0M | ||
| Q1 24 | $9.8M | $-63.3M |
毛利率CBATRGNX
| Q4 25 | 7.3% | — | ||
| Q3 25 | 8.0% | — | ||
| Q2 25 | 11.0% | — | ||
| Q1 25 | 13.7% | — | ||
| Q4 24 | 13.1% | 70.2% | ||
| Q3 24 | 15.6% | 48.8% | ||
| Q2 24 | 26.6% | 52.5% | ||
| Q1 24 | 31.9% | 72.6% |
营业利润率CBATRGNX
| Q4 25 | -13.6% | -190.0% | ||
| Q3 25 | -6.6% | -176.3% | ||
| Q2 25 | -8.7% | -296.3% | ||
| Q1 25 | -8.2% | 13.6% | ||
| Q4 24 | -26.0% | -242.1% | ||
| Q3 24 | -1.9% | -256.6% | ||
| Q2 24 | 12.4% | -251.3% | ||
| Q1 24 | 17.4% | -408.8% |
净利率CBATRGNX
| Q4 25 | -12.5% | -221.3% | ||
| Q3 25 | 4.4% | -208.3% | ||
| Q2 25 | -7.6% | -331.8% | ||
| Q1 25 | -4.5% | 6.8% | ||
| Q4 24 | -17.8% | -241.3% | ||
| Q3 24 | 0.0% | -246.3% | ||
| Q2 24 | 13.5% | -237.7% | ||
| Q1 24 | 16.7% | -405.4% |
每股收益（稀释后）CBATRGNX
| Q4 25 | $-0.08 | $-1.30 | ||
| Q3 25 | $0.03 | $-1.20 | ||
| Q2 25 | $-0.03 | $-1.38 | ||
| Q1 25 | $-0.02 | $0.12 | ||
| Q4 24 | $-0.05 | $-0.99 | ||
| Q3 24 | $0.00 | $-1.17 | ||
| Q2 24 | $0.07 | $-1.05 | ||
| Q1 24 | $0.11 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.3M | $230.1M |
| 总债务越低越好 | $4.1M | — |
| 股东权益账面价值 | $112.7M | $102.7M |
| 总资产 | $426.2M | $453.0M |
| 负债/权益比越低杠杆越低 | 0.04× | — |
8季度趋势，按日历期对齐
现金及短期投资CBATRGNX
| Q4 25 | $8.3M | $230.1M | ||
| Q3 25 | $10.5M | $274.2M | ||
| Q2 25 | $45.7M | $323.3M | ||
| Q1 25 | $9.6M | $267.9M | ||
| Q4 24 | $11.0M | $234.7M | ||
| Q3 24 | $24.2M | $255.5M | ||
| Q2 24 | $44.1M | $290.4M | ||
| Q1 24 | $23.8M | $338.7M |
总债务CBATRGNX
| Q4 25 | $4.1M | — | ||
| Q3 25 | $4.8M | — | ||
| Q2 25 | $4.9M | — | ||
| Q1 25 | $4.1M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CBATRGNX
| Q4 25 | $112.7M | $102.7M | ||
| Q3 25 | $121.4M | $161.5M | ||
| Q2 25 | $118.2M | $213.7M | ||
| Q1 25 | $120.8M | $274.2M | ||
| Q4 24 | $121.7M | $259.7M | ||
| Q3 24 | $131.2M | $301.4M | ||
| Q2 24 | $126.6M | $348.3M | ||
| Q1 24 | $120.9M | $390.7M |
总资产CBATRGNX
| Q4 25 | $426.2M | $453.0M | ||
| Q3 25 | $363.9M | $525.2M | ||
| Q2 25 | $333.1M | $581.0M | ||
| Q1 25 | $311.5M | $490.9M | ||
| Q4 24 | $302.2M | $466.0M | ||
| Q3 24 | $293.5M | $519.1M | ||
| Q2 24 | $279.6M | $569.4M | ||
| Q1 24 | $286.5M | $629.2M |
负债/权益比CBATRGNX
| Q4 25 | 0.04× | — | ||
| Q3 25 | 0.04× | — | ||
| Q2 25 | 0.04× | — | ||
| Q1 25 | 0.03× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $29.8M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $16.1M | $-52.8M |
| 自由现金流率自由现金流/营收 | 27.3% | -174.0% |
| 资本支出强度资本支出/营收 | 23.4% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $3.9M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流CBATRGNX
| Q4 25 | $29.8M | $-52.3M | ||
| Q3 25 | $14.6M | $-56.0M | ||
| Q2 25 | $13.8M | $-49.3M | ||
| Q1 25 | $-9.6M | $33.6M | ||
| Q4 24 | $9.6M | $-31.6M | ||
| Q3 24 | $19.7M | $-40.5M | ||
| Q2 24 | $2.9M | $-45.5M | ||
| Q1 24 | $7.4M | $-55.5M |
自由现金流CBATRGNX
| Q4 25 | $16.1M | $-52.8M | ||
| Q3 25 | $6.0M | $-56.5M | ||
| Q2 25 | $4.1M | $-49.7M | ||
| Q1 25 | $-22.3M | $32.6M | ||
| Q4 24 | $3.9M | $-32.7M | ||
| Q3 24 | $16.5M | $-40.9M | ||
| Q2 24 | $2.5M | $-46.0M | ||
| Q1 24 | $-454.0K | $-56.0M |
自由现金流率CBATRGNX
| Q4 25 | 27.3% | -174.0% | ||
| Q3 25 | 9.9% | -189.9% | ||
| Q2 25 | 10.2% | -232.8% | ||
| Q1 25 | -63.9% | 36.6% | ||
| Q4 24 | 15.5% | -154.2% | ||
| Q3 24 | 37.1% | -168.9% | ||
| Q2 24 | 5.2% | -206.2% | ||
| Q1 24 | -0.8% | -358.5% |
资本支出强度CBATRGNX
| Q4 25 | 23.4% | 1.7% | ||
| Q3 25 | 14.1% | 1.7% | ||
| Q2 25 | 23.8% | 1.8% | ||
| Q1 25 | 36.3% | 1.2% | ||
| Q4 24 | 22.5% | 5.1% | ||
| Q3 24 | 7.0% | 1.3% | ||
| Q2 24 | 0.9% | 2.1% | ||
| Q1 24 | 13.4% | 3.6% |
现金转化率CBATRGNX
| Q4 25 | — | — | ||
| Q3 25 | 5.51× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 1115.72× | — | ||
| Q2 24 | 0.46× | — | ||
| Q1 24 | 0.76× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CBAT
| Manufacturing Lithium Batteries | $28.0M | 48% |
| Residential Energy Supply And Uninterruptable Supplies | $17.8M | 30% |
| Light Electric Vehicles | $12.9M | 22% |
| Precursor | $108.0K | 0% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
